Monopar Therapeutics (MNPR) director sells 4,090 shares after option exercises
Rhea-AI Filing Summary
Monopar Therapeutics (MNPR) director Kim R. Tsuchimoto reported an amended set of transactions on August 26, 2026, correcting a prior Form 4. The director exercised stock options for 2,055 shares at an exercise price of $30.00 and 2,035 shares at $14.00, receiving an equal number of common shares. On the same date, a total of 4,090 common shares were sold in multiple trades at weighted average prices between $108.83 and $113.84 per share, with underlying trade ranges from $108.07 to $114.34. All option exercises and sales were effected pursuant to a Rule 10b5-1 Plan executed on May 27, 2026. Following these transactions, 11,486 shares are reported as held indirectly by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 4,090 shares ($365K approx. pre-tax spread)
Exercise and Sale
11 txns
Insider
Tsuchimoto Kim R
Role
Director
Sold
4,090 shs ($456K)
Approx. gross sale proceeds
$456K
Approx. exercise cost
$90K
Approx. pre-tax spread
$365K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F2 | 2,055 | $0.00 | $0.00 |
| Exercise | Stock Option F1, F3 | 2,035 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,055 | $30.00 | $62K |
| Exercise | Common Stock F1 | 2,035 | $14.00 | $28K |
| Sale | Common Stock F1, F4 | 485 | $108.83 | $53K |
| Sale | Common Stock F1, F5 | 615 | $109.56 | $67K |
| Sale | Common Stock F1, F6 | 700 | $110.65 | $77K |
| Sale | Common Stock F1, F7 | 1,098 | $111.84 | $123K |
| Sale | Common Stock F1, F8 | 602 | $112.93 | $68K |
| Sale | Common Stock F1, F9 | 590 | $113.84 | $67K |
| holding | Common Stock F10 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 14,305 shares (Direct);
Common Stock — 0 shares (Direct);
Common Stock — 11,486 shares (Indirect, See footnote)
Footnotes (10)
- F1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
- F2. On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.
- F3. On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F10. Represents shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Key Figures
Options exercised at $30.00: 2,055 shares
Options exercised at $14.00: 2,035 shares
Total common shares sold: 4,090 shares
+5 more
8 metrics
Options exercised at $30.00
2,055 shares
Stock options exercised into common stock on August 26, 2026 at $30.00 per share
Options exercised at $14.00
2,035 shares
Stock options exercised into common stock on August 26, 2026 at $14.00 per share
Total common shares sold
4,090 shares
Common stock sales on August 26, 2026 reported with code S
Weighted average sale prices
$108.83–$113.84 per share
Range of weighted average prices across the reported sale transactions
Underlying trade price ranges
$108.07–$114.34 per share
Price ranges for individual trades described in footnotes (4)–(9)
Indirectly held shares
11,486 shares
Common shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015, after transactions
Stock option grant 2018
8,220 shares
Maximum shares purchasable under options granted August 28, 2018, per vesting footnote
Stock option grant 2022
16,279 shares
Maximum shares purchasable under options granted February 2, 2022, per vesting footnote
Key Terms
Rule 10b5-1 Plan, weighted average price, derivative security, indirect
4 terms
Rule 10b5-1 Plan regulatory
"Both the option exercises and the sales of common stock were effected pursuant to a Rule 10b5-1 Plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
indirect financial
"Represents shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015"
FAQ
What insider transactions did MNPR director Kim R. Tsuchimoto report in this amended Form 4?
The director reported exercising stock options for 4,090 shares of Monopar Therapeutics common stock and selling 4,090 shares on August 26, 2026, correcting a prior Form 4 that omitted the option exercises.
At what prices were the MNPR stock options exercised in this filing?
Kim R. Tsuchimoto exercised options for 2,055 shares at an exercise price of $30.00 per share and 2,035 shares at an exercise price of $14.00 per share, receiving an equal number of Monopar Therapeutics common shares.
Were the MNPR insider transactions made under a Rule 10b5-1 trading plan?
Yes. The company reports that both the option exercises and the sales of Monopar Therapeutics common stock were effected pursuant to a Rule 10b5-1 Plan executed by Kim R. Tsuchimoto on May 27, 2026.
What is being corrected by this amended Form 4 for MNPR?
The amendment states that the original Form 4 filed on August 27, 2026 inadvertently omitted two option exercises that occurred before the reported sales. This Form 4/A adds those option exercises while keeping the previously reported sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
